Sitagliptin Impurities

Sitagliptin is used to improve glycemic control in adults with type 2 diabetes, as monotherapy or in combination with other oral agents or insulin when appropriate. It enhances endogenous incretin hormones to increase glucose-dependent insulin release and reduce glucagon, lowering fasting and postprandial blood glucose.

Metformin is a biguanide that primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, and is usually first-line therapy. Sitagliptin is a DPP-4 inhibitor that works by increasing incretin levels to stimulate insulin secretion and suppress glucagon in a glucose-dependent manner. Metformin often causes gastrointestinal effects and can produce modest weight loss or neutrality, while sitagliptin is generally weight neutral and has a different adverse event profile and dosing considerations, including renal dose adjustments for sitagliptin.

The most commonly reported adverse events are mild and include nasopharyngitis, upper respiratory infection and headache. Less common but serious events can include pancreatitis and hypersensitivity reactions, so new severe abdominal pain or signs of allergic reaction should be evaluated promptly.

Sitagliptin is primarily renally excreted, so renal function must be assessed before and during treatment. Dose reduction is recommended for moderate and severe renal impairment and end stage renal disease. With appropriate dose adjustment and monitoring, sitagliptin can be used in patients with renal impairment, but it is not recommended to use the standard dose without modification in reduced renal function.